News from suneva medical, inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Feb 21, 2013, 12:22 ET Suneva Medical Expands its Operations to Santa Barbara

 Suneva Medical, Inc., a privately-held aesthetics company, today announced that it has expanded from its San Diego base to open an office in...


Sep 18, 2012, 08:00 ET Suneva Medical Completes Enrollment and Initial Treatment of Patients in Phase III Acne Scar Study

Suneva Medical, Inc., a privately-held aesthetics company, today announced that it has completed the enrollment and initial treatment of patients...


Mar 05, 2012, 12:20 ET Histogen Signs License Agreement with Suneva Medical for Cell Conditioned Media-based Aesthetic Products

 Histogen Inc., a regenerative medicine company, and Suneva Medical, a privately-held aesthetics company, today announced that they have...


Jun 29, 2011, 07:50 ET Suneva Medical Announces Canadian Approval of Bellafill™

Suneva Medical, a privately-held aesthetic medical device company, today announced the expansion of its core aesthetics injectable business with...


May 04, 2010, 14:07 ET Leading Plastic Surgeons Report Positive Data on Artefill(R) at Key Society Meetings

Suneva Medical, a privately-held aesthetic medical device company, today announced that Steven R. Cohen, M.D., F.A.C.S, Clinical Professor,...


Feb 02, 2010, 10:56 ET Two Studies Find Artefill(R) to Be a Long-Term Treatment Option for Facial Lipoatrophy

Suneva Medical, a privately-held aesthetic medical device company, today announced that two clinical studies suggest Artefill may be a safe,...


Jan 25, 2010, 09:00 ET Suneva Medical Announces Positive Interim Data From Five-Year Safety and Patient Satisfaction Study on Artefill(R)

Suneva Medical, a privately-held aesthetic medical device company, today announced 18-month interim results from its prospective, open-label,...